Device Trial Radar · NCT07856745
Efficacy and Safety of FLEXIPORT Implantable Port in Chemotherapeutic Treatments
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Apr 1, 2024
Primary completion
Feb 24, 2026
Study completion Feb 24, 2026
Sponsor
- Lead sponsor
- Portal Access Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess, in a clinical setting, the efficacy and the safety of FLEXIPORT, a totally implantable venous access device (TIVAD) designed to provide a repeated access to the vascular system, in patients with malignant diseases requiring central venous access for administration of chemotherapeutic treatments. The main question it aims to answer is what is the success rate of the device in providing vascular access, with the success rate defined as proportion of participants with a functioning device at 180 days post-implantation or at the time of removal, if the latter occurred for reasons other than adverse event or device deficiency.
Conditions
- Neoplasms
Interventions
FLEXIPORTDevice
FLEXIPORT is a totally implantable venous access device (TIVAD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success rateTime frame: within 6-8 months post-implantation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinica Canela
La Romana, Dominican Republic
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.